171 related articles for article (PubMed ID: 24892422)
21. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia.
Demeter J; Hamed A; László S; Suvajdzic N; Aigner S; Börner B; Staiger C
Transfus Med; 2023 Apr; 33(2):165-173. PubMed ID: 36448274
[TBL] [Abstract][Full Text] [Related]
22. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
23. Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.
Shahgholi E; Vosough P; Sotoudeh K; Arjomandi K; Ansari S; Salehi S; Faranoush M; Ehsani MA
Indian J Pediatr; 2008 Dec; 75(12):1231-5. PubMed ID: 19190878
[TBL] [Abstract][Full Text] [Related]
24. A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience.
Alioglu B; Ercan S; Tapci AE; Zengin T; Yazarli E; Dallar Y
Blood Coagul Fibrinolysis; 2013 Jul; 24(5):505-9. PubMed ID: 23470649
[TBL] [Abstract][Full Text] [Related]
25. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura.
Erduran E; Aslan Y; Gedik Y; Orhan F
Turk J Pediatr; 2003; 45(4):295-300. PubMed ID: 14768792
[TBL] [Abstract][Full Text] [Related]
26. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.
Blanchette V; Imbach P; Andrew M; Adams M; McMillan J; Wang E; Milner R; Ali K; Barnard D; Bernstein M
Lancet; 1994 Sep; 344(8924):703-7. PubMed ID: 7915773
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.
Moy JN; Scharenberg AM; Stein MR; Suez D; Roberts RL; Levy RJ; Ballow M; Fasano MB; Dash CH; Leach SJ
Clin Exp Immunol; 2010 Dec; 162(3):510-5. PubMed ID: 21070209
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
29. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.
Warrier I; Bussel JB; Valdez L; Barbosa J; Beardsley DS
J Pediatr Hematol Oncol; 1997; 19(3):197-201. PubMed ID: 9201140
[TBL] [Abstract][Full Text] [Related]
31. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.
Gereige RS; Barrios NJ
P R Health Sci J; 2000 Mar; 19(1):15-8. PubMed ID: 10761200
[TBL] [Abstract][Full Text] [Related]
32. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
Blackhouse G; Xie F; Levine MA; Campbell K; Assasi N; Gaebel K; O'Reilly D; Tarride J; Goeree R
J Popul Ther Clin Pharmacol; 2012; 19(2):e166-78. PubMed ID: 22580389
[TBL] [Abstract][Full Text] [Related]
33. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
34. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
Tarantino MD; Madden RM; Fennewald DL; Patel CC; Bertolone SJ
J Pediatr; 1999 Jan; 134(1):21-6. PubMed ID: 9880444
[TBL] [Abstract][Full Text] [Related]
35. Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura.
Kumar M; Vik TA; Johnson CS; Southwood ME; Croop JM
Am J Hematol; 2005 Mar; 78(3):181-7. PubMed ID: 15726607
[TBL] [Abstract][Full Text] [Related]
36. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
38. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura.
Ramadan KM; El-Agnaf M
Clin Lab Haematol; 2005 Aug; 27(4):267-9. PubMed ID: 16048495
[TBL] [Abstract][Full Text] [Related]
40. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
